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We have previously shown that a long noncoding RNA transcript Heg is negatively correlated with TSH receptor autoantibodies
(TRAb) in patients with untreated Graves’ disease and with CD14 mRNA in treated patients and controls. Thus patients with
high concentrations of Heg RNA have low levels of TRAb or CD14 mRNA, respectively. Here we show that an additional factor,
gene expression of Cdk1 in mononuclear cells, is positively related to concentrations of TRAb in patients with untreated Graves’
disease. Cdk1 mRNA is very important for regulation of cell cycle activity. It is well known that TRAb decrease signiﬁcantly during
treatment with antithyroid drugs. This decrease during treatment cannot be explained by Heg RNA, which remains unchanged.
Cdk1 mRNA decreased signiﬁcantly during treatment to values below values obtained in normal subjects. Thus both Heg RNA
and Cdk1 mRNA may inﬂuence the level of TSH receptor autoantibodies but by diﬀerent mechanisms.
1.Introduction
We have previously shown that a long non-coding RNA
transcript Heg in MNC (GenBank EU137727) is negatively
correlated with TRAb in patients with early and untreated
Graves’ disease and with CD14 mRNA in treated patients
and in normal subjects. Furthermore, transfection studies
with fragments of Heg (exogenous Heg) decreased CD14
mRNA [1] and increased TLR7 and INF-γ mRNA in MNC
(unpublished results). Low CD14 values may reduce IL-
12 and activation of monocyte-dendritic cell signaling and
autoantibody production [2]. It cannot be excluded that Heg
may be protein-coding and the existence of open reading
frames within the Heg sequence warrants further study [3].
TRAbdecreaseduringtreatmentwithantithyroiddrugs.The
mechanism has not been clariﬁed [4–8]. The primary aim
of the present study was therefore to examine if changes in
TRAb during antithyroid treatment were related to changes
in Heg RNA and CDl4 mRNA. Secondly, we wanted to
examine if TRAb was related to Cdk1 mRNA, which is an
important factor for regulation of cell cycle activity [9].
2.Subjects
All subjects gave informed consent. The study protocol was
approved by the Ethics Committee of Copenhagen County
and was in compliance with the declaration of Helsinki II.
Samples were obtained from three main study groups.
(1) Seventeen patients with Graves’ disease were studied
at the time of diagnosis before treatment with
antithyroid drugs had begun. The mean age was
4 8y e a r s( r a n g ef r o m3 5t o6 7y e a r s ) .S i x t e e nw e r e
females and one a male. The median level of TRAb
was 11.4IU/l (range of 5.8 (25%)–16.1 (75%)).
(2) Twenty patients with Graves’ disease were studied
after treatment had been initiated. The mean age
w a s4 1y e a r s .F i f t e e nw e r ef e m a l e sa n d5w e r em a l e s .
mRNA levels were not measured in these patients
before treatment was started but at a followup after
median 11 months of treatment (range of 4 (25%)–
17.5 (75%)). At the time of examination thyroid
hormones were normalized in approximately half of2 ISRN Endocrinology
the subjects and 11 subjects had minor elevations in
T3 values or suppressed TSH levels. In the majority
ofpatients,theTRAbleveldecreasedfromthetimeof
diagnosis to the time of the study. Six of the patients
were treated with PTU and 14 patients were treated
with Thiamazol. TRAb were available both before
and after treatment had been initiated, but no gene
expression levels were available before treatment had
started. The median TRAb level before treatment was
started was 13.5IU/l (range 9–21.5) and 6.5 (range
2.5–20) during treatment at the time of the present
investigation (P<0.004).
(3) Eighteen normal subjects were all healthy with a
mean age of 45 years. Ten were females and eight
males.
3. Methods
Methods applied have been described previously [1, 10]a n d
will only brieﬂy be mentioned here.
3.1. Isolation of RNA. RNA was isolated from 5 × 106 MNC.
For isolation of RNA, we applied the Qiaamp Blood Mini
Kit (Qiagen Gmbh, Hilden, Germany). Both total RNA and
DNA concentrations were determined.
3.2. Quantiﬁcation of Heg RNA, CD14 mRNA, and Cdk1
mRNA in MNC. mRNA was quantiﬁed by RT-PCR-HPLC
[1, 10]. HPLC was applied to separate the peak value of the
speciﬁc standard and the mRNA to be measured.
3.3. Primers and Construction of Internal Standards. The
oligonucleotide primers were synthesized at DNA Technol-
ogy (Aarhus, Denmark) or by MWG (Germany).
For quantiﬁcation of the Heg RNA, we used the following
set of primers:
Upper primer 5 -GCG CCT GGT ATT AGA T-3 
L o w e rP r i m e r5  -CTT TTT CAT ATC CCG ATC TT-
3 
CD14 mRNA
Upper primer 5 -TTC TAA AGC GCG TCG ATG C-
3 
Lower primer 5 -ATT CTG GAT GGC CGG GAA
CTT-3 
Cdk1 mRNA




An internal standard RNA for Heg and other mRNAs
were constructed using the above-mentioned sets of primers
and the PCR-MIMIC construction kit from Clontech (BD
Biosciences Clontech, Palo Alto, CA). The size of the internal
standard (number of bases) was designed to be 239 for Heg,
240 for CD14, and 240 for Cdk1. Amounts of internal RNA
standardaddedtoRT-PCRwereforHeg0.12amol,forCD14
4.36amol, and for Cdk1 19.5zmol.
3.4. Quantiﬁcation of PCR Products by HPLC. The HPLC
system consisted of a TSK DEAE-NPR column (4.6mm I.D.
× 35mm) thermostated at 30◦C. The pump was a WATERS
Model 616 gradient pump controlled by Empower software,
which was also applied for data acquisition and processing.
Detection was by an Applied Biosystems Model 759A UV-
detector at 254nm. The PCR product was quantiﬁed relative
to the internal standard using areas and corrected for
diﬀerent sizes of the two products. mRNA concentrations
wereexpressedasamolmRNA/μg DNA or as zmol mRNA/μg
DNA.
3.5. Validation of the Technique and Reproducibility. These
results have been described previously [1].
3.6. Hormones. Thyroid hormones and TRAb were mea-
sured as described earlier [1].
3.7. Statistics. The statistical analysis was performed by the
SigmaStat 3.1.1 (SPSS Inc., Chicago, IL). The following sta-
tistical tests were applied: Student’s t-test, one-way ANOVA,
linear regression analysis, and multiple regression analysis. A
P value < 0.05 was considered signiﬁcant.
4. Results
Multiple regression analysis was performed in untreated
patientswithGraves’diseasewithlogTRAbasthedependent
variable and Heg RNA amol/μg DNA and log Cdk1 mRNA
zmol/μg DNA as independent variables. Heg RNA was as
reportedpreviouslynegativelycorrelatedwithlogTRAb(P<
0.001). Cdk1 mRNA was positively related to TRAb (P<
0.002), and including Cdk1 RNA in the regression analysis
increased the r value (numerically) from −0.61 to −0.83
(r =− 0.83; P<0.001):
log10TRAb IU/l = 1.209 −









Figure 1 shows the negative relationship observed
between log TRAb and the ratio Heg RNA/Log Cdk1 mRNA
(r =− 0.82; P<0.001). Note that Cdk1 RNA was only
related to TRAb provided Heg RNA was included in the
statistical analysis. No relationship was established between
Cd14 mRNA and Cdk1 mRNA in treated patients with
Graves’ disease or in normal controls.
TRAb concentrations but not Heg RNA decreased
approximately 50% (from a median level of 13.5 to 6.5IU/l;
P<0.004) during treatment in the 20 patients with Graves’



















































Ratio Heg RNA amol/Log10 Cdk1 mRNA zmol
0.04 0.05 0.06 0.07 0.08 0.09 0.1 0.11 0.12
Figure 1: The relationship between log10 TSH receptor autoan-
tibodies (TRAb) IU/Liter and the ratio Heg RNA amol per μg
DNA/Log10 Cdk1 mRNA zmol per μgD N A .r =− 0.82; P< 0.001.
Table 1: Cdk1 mRNA concentrations expressed in zmol/μgD N A
(median and 25% and 75% ranges) in untreated and treated
patients with Graves’ disease and in controls.
Untreated patients Treated patients Normal subjects
33 (22 to 39) 13 (10–17)∗ 27 (18–34)
∗Signiﬁcantly diﬀerent from the two other groups (P<0.001).
patients and normal subjects. (Table 1;A N O V AP<0.001).
ThecalculatedTRAbvaluesobtainedfromtheregressionline
above after an assumed reduction in Cdk1 mRNA values of
approximately 50% also resulted in a decrease in TRAb of
50%. Note that the Cdk1 mRNA decreased below the level
observed in normal subjects, and levels were not diﬀerent in
untreated patients and controls.
5. Discussion
Patients with high Heg RNA concentrations had low TRAb
values or CD14 mRNA values in untreated patients with
Graves’ disease and in treated patients and controls, respec-
tively [1]. The present study showed, that decrements in
TRAb in treated patients with Graves’ disease could not be
related to changes in Heg RNA. In patients with untreated
Graves’ disease, multiple regression analysis with Heg RNA
and Cdk1 mRNA as independent variables showed that
Cdk1 mRNA values were positively related to TRAB. The
r value increased from −0.61 to −0.83 as compared to
simple regression analysis with Heg RNA as the variable.
The main ﬁnding in the present study is, however, the
signiﬁcant decrease in Cdk1 mRNA in treated patients with
Graves’ disease as compared with the other two groups. This
may suggest that the decrease in TRAb during antithyroid
treatment was related to a decrease in cell cycle activity.
Note, however, that the concentration of Cdk1 mRNA was
not diﬀerent in untreated patients and controls, suggesting
that the decrease in Cdk1 values during treatment was a
speciﬁceﬀectofantithyroiddrugsandnotduetodecrements
in thyroid hormone concentrations. Further studies are
required to establish the mechanism by which changes in
cell cycle activity and antithyroid drugs may decrease TRAb.
Our results suggest that there are two diﬀerent factors, which
may inﬂuence the level of TRAb. The mechanism is likely
to be diﬀerent. Transfection studies have shown that Heg
RNA may reduce gene expression of CD14 mRNA probably
by activating TLR7 and INF-γ. This may reduce IL-12 and
decrease activation of monocyte-dendritic cell signaling.
There is no reason to assume, that this eﬀect is speciﬁc for
patients with Graves’ disease. The decrease in CDk1 mRNA
andinTRA bislik elytobeaspeciﬁceﬀectofantithyroiddrug
treatments, and at present it is unclear if this eﬀect is seen
only in patients with Graves’ disease. Clearly further studies
are required to elucidate the mechanism by which Cdk1 and
Heg may regulate TRAb concentrations.
6. Conclusion
The present study suggests that two diﬀerent factors may
regulate concentrations of TRAb. A noncoding RNA tran-
script Heg is negatively related to TRAb in untreated patients
with Graves’ disease and to CD14 mRNA in treated patients
and controls. Transfection experiments have also shown that
Heg RNA decreased Cd14 mRNA. The decrease in TRAb
observed during antithyroid treatment cannot be explained
by Heg RNA, but may be due to a decrease in Cdk1 mRNA,
which is important for regulation of cell cycle activity. Gene
expression of Cdk1 decreases during treatment to levels
below values observed in normal subjects, suggesting that
this is a pharmacological eﬀect of antithyroid drugs.
Abbreviations
MNC: Mononuclear cells
TRAb: TSH receptor autoantibodies.
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